Citations

Clear

3138 citation(s) found for "Smith, AM".

A single item for overall side effect impact: Association with clinician-reported adverse events and global health
Roydhouse, Jessica , Zola, Anne , Basch, Ethan, Cella, David, Smith, Mary Lou , Thanarajasingam, Gita , Peipert, John Devin , Basch, Ethan , Cella, David , Peipert, John Devin , Breslin, Monique C. , Calvert, Melanie

Mayo Clinic

Clinical Trials | January 6, 2026 | Volume: 23 | Issue: 2 | Pages: 155-165

10.1177/17407745251405412 | PMID 41491584 Get It

Background: There is growing recognition of the importance of patient-reported tolerability in complementing traditional clinician-reported safety evaluation of cancer therapies. Recent regulatory guidance listed the evaluation of overall side effect impact as a core patient-reported outcome in oncology clinical trials. A single item (‘GP5’) that asks about side effect bother is included in the Functional Assessment of Chronic Illness Therapy and has been used to capture overall side effect impact. This paper sought to expand the evidence base for GP5 by examining its association with clinician-reported treatment-emergent adverse events and patient-reported global health. Methods: We examined six commercial cancer clinical trials that collected GP5. The patient population was drawn from the safety population and the analysis focused on the first on-treatment assessment. Clinician-reported adverse events were classified as symptomatic if such adverse events were considered amenable to patient self-reporting (e.g. nausea). Chi-square tests and Pearson’s correlation were used to examine associations. We considered adverse event grade and frequency, both for symptomatic adverse events and any type of adverse events. Global health was measured using the visual analogue scale of the EuroQol-5 Dimensions-3 Levels measure. ‘Moderate-severe’ bother was characterised as scores of 2–4 on a 0–4 point scale for GP5, and ‘severe’ bother was characterised as scores of 3–4. Analyses were conducted separately for each trial. Results: Data from 3,557 patients were included. Across the trials, most (71.7%–94.2%) patients had an adverse event of some kind, but fewer (17.1%–44.4%) had an adverse event of grade 3 or higher. In general, fewer than 50% of patients (20.6%–44.2%) reported moderate-severe bother and 5.8%–17.% reported severe bother. There were consistent, albeit not always statistically significant, associations between GP5 and adverse events, and GP5/global health correlations ranged from −0.17 to −0.41. Discussion: GP5 is associated with both clinician- and patient-reported symptoms, suggesting its validity and usefulness as part of comprehensive tolerability assessment of cancer trials.
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma
Alderuccio, Juan Pablo , Baggio, Diva , Han, Sunwoo , Nizamuddin, Imran , Saha, Aditi, Dong, Ning , Wang, Yucai, Cherng, Hua‐Jay J. , Wagner-Johnston, Nina D., Desai, Amrita, Geethakumari, Praveen Ramakrishnan , Moyo, Tamara K. , Sandoval‐Sus, Jose , EPPERLA, NARENDRANATH, Kamdar, Manali, Tavarozzi, Rita , Danilov, A., Tun, H., Munoz, Javier, Narkhede, Mayur , Maraj, Adrian Matthew, Osborne, Wendy , Calvert, Victoria, El‐Sharkawi, Dima , Hilali, Ammar, Collins, Graham P., Elmusharaf, Nagah, Santarsieri, Anna , Karim, Farheen, Monick, Sarah, Trutzer, Iris Margalit, Can, Jones, Ayers, Amy , Feo, Jacopo Calabrese De, Ghosh, Nilanjan, Treitman, Rachel, Okcu, Izel, Hann, William D., Barrett, Aisling , Deshani, Vismay, Cwynarski, K., Wang, Yucai , Saha, Aditi , Ghione, Paola , Khwaja, Jahanzaib , Saha, Aditi , Wang, Yucai , Cherng, Hua-Jay J , Tolu, Seda , Wagner-Johnston, Nina , Ollila, Thomas A , Grover, Natalie S , Koff, Jean L , Ramakrishnan Geethakumari, Praveen , Sandoval-Sus, Jose , Epperla, Narendranath , Wallace, Danielle S , Kamdar, Manali , Tun, Han W , Narkhede, Mayur S , Rhodes, Joanna , Okosun, Jessica , El-Sharkawi, Dima , Collins, Graham P , Linton, Kim M , Santarsieri, Anna , Baidoun, Firas , Monick, Sarah E, Calabrese De Feo, Jacopo , Sharp, John , Ghosh, Nilanjan , Okcu, Izel , Hann, William , Barrett, Aisling , Deshani, Vismay , Kahl, Brad S , Chavez, Julio C , Olszewski, Adam J , Ghione, Paola , Dong, Ning, Wagner‐Johnston, Nina D. , Grover, Natalie S. , Koff, Jean L. , Epperla, Narendranath , Wallace, Danielle , Kamdar, Manali , Tun, Han W. , Muñoz, Javier, Rhodes, Joanna , Prica, Anca A. , Kühnl, Andrea , Maraj, Adrian , Smith, Jeff , Calvert, Victoria, Linton, Kim , Baidoun, Firas , Sharp, John , Kallam, Avyakta , Abeyakoon, Chathuri , Kahl, Brad S. , Olszewski, Adam J. , Cwynarski, Kate

Mayo Clinic

Blood | January 5, 2026 | Volume: 147 | Issue: 16 | Pages: 1814-1827

10.1182/blood.2025031455 | PMID 41490516 Get It

Abstract Secondary central nervous system (CNS) large B-cell lymphoma (SCNSL) occurs in the de novo setting, as a CNS-isolated relapse, or synchronous (concomitant CNS and systemic) relapse. SCNSL is a devastating event without therapeutic consensus. Thus, we aimed to evaluate treatment outcomes in an international cohort. Progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR, estimated using competing-risk models) were reported. Prognostic factors were identified in a 6-month landmark multivariate analysis. Outcomes after thiotepa autologous stem cell transplant (ASCT) and chimeric antigen receptor (CAR) T-cell therapy (CAR-T) delivered at relapse were compared after propensity score matching (PSM). A total of 1139 patients were included in the analysis (de novo: 537; relapsed SCNSL: 602). Two-year PFS estimates were 40.4%, 43.9%, and 16.2% for de novo SCNSL, CNS-isolated relapse, and synchronous relapse, respectively. Patients with CNS-isolated relapse demonstrated low rates of systemic recurrence (24-month CIR, 6%). Thiotepa-ASCT correlated with longer survival in de novo SCNSL (PFS: hazard ratio [HR], 0.57; P = .005; and OS: HR, 0.62; P = .023) and CNS-isolated relapses (PFS: HR, 0.55; P = .002; and OS: HR, 0.39; P< .0001). ASCT (thiotepa or no thiotepa) also associated with improved survival in synchronous relapses (PFS: HR, 0.57; P = .023; and OS: HR, 0.48; P = .019). Higher survival with thiotepa-ASCT than CAR-T was observed after PSM (PFS: HR, 0.45; P = .005 and OS: HR, 0.41; P = .014). These data support thiotepa-ASCT in eligible patients, particularly de novo disease and CNS-isolated relapses. CNS-isolated relapse was infrequently associated with systemic recurrence, supporting treatment regimens adopted from primary CNS lymphoma.
Mucus plugs in chronic obstructive pulmonary disease are heterogeneous in size and shape and occur in relatively large airways
Farooqui, Omar, Elicker, Brett M. , Henry, Travis, Hahn, Lewis D. , Kallianos, Kimberly , Han, MeiLan K, Barr, R Graham, Smith, Benjamin M, Comellas, Alejandro P, Bon, Jessica , Hansel, Nadia, Wells, J Michael, Paine, R, Barjaktarevic, I., Schroeder, Joyce , Woodruff, Prescott G, Huang, B J, FAHY, JOHN V., Wells, J. Michael , Comellas, Alejandro P. , Smith, Benjamin M. , Schroeder, Joyce D , Comellas, Alejandro P , Wells, J Michael , Henry, Travis S, Han, MeiLan King , Barr, R. Graham, Smith, Benjamin M., Hansel, Nadia, Barjaktarević, Igor , Woodruff, Prescott G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | January 5, 2026 | Volume: 212 | Issue: 2 | Pages: 268-276

10.1093/ajrccm/aamaf138 | PMID 41738094 Get It

Abstract Rationale Mucus plugs occur in chronic obstructive pulmonary disease (COPD), but little is known about their size and airway location or whether these mucus plug features change as emphysema worsens. Methods Computed tomographic lung scans from 31 participants with COPD from the SubPopulations and InteRmediate Outcomes In COPD Study (SPIROMICS) cohort were analyzed to quantify mucus plug size and airway location and extent of emphysema. Radiologist annotations of mucus plugs were incorporated in an image processing pipeline to generate size and location information. Emphysema was quantified as the percentage of voxels less than -950 Hounsfield units. Measurements and Main Results The length distribution of 563 annotated mucus plugs varied from 2 to 50 mm. The distribution was multimodal, and an 11-mm length defined short (“stubby,” ≤11 mm) and long (“stringy,” >11 mm) plug phenotypes, with stubby plugs being most common (64%). Mucus plugs localized predominantly to airway generations 6 to 9, and their prevalence was highest in lower lobes. On a lobar basis, the mucus plug number decreased as emphysema percentage increased, whereas average mucus plug volume tended to increase. Conclusion COPD is characterized by mucus plugs of varying size and shape, and emphysematous lung regions may be differentially susceptible to formation of these plugs. The location of mucus plugs in segmental and subsegmental airways in COPD makes them amenable to treatment with inhaled medications or bronchoscopy.
Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102)
Wood, Marie , Pinsky, Paul F. , Novotny, Paul J. , Leevan, Elyse , Weiss, Matthias , Edelman, Dan, Watson, Mark A. , Patriotis, Christos , Merker, Jason D. , Prorok, Philip C. , Wen, Yujia , Rubinstein, Wendy S. , Dragnev, Konstantin H. , Katki, Hormuzd A. , Chow, Selina , Kemeny, Margaret, Gautam, Umang, Reddy, Aswanth , Burak, William E. , Piantadosi, Steven , Minasian, Lori M. , Wood, Marie E , Edelman, Dan C , Watson, Mark , Dragnev, Konstantin , Skarlupka, Amanda L , Katki, Hormuzd A , Chow, Selina , Kemeny, Margaret , Piantadosi, Steven , Weiss, Matthias

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 5, 2026 | Volume: 118 | Issue: 4 | Pages: 730-736

10.1093/jnci/djag001 | PMID 41499420 Get It

Abstract Background Reference sets are needed to evaluate performance of multi-cancer detection (MCD) assays. The National Cancer Institute funded the Alliance reference set study to assess MCDs for use in future trials. Methods Individuals with cancer and controls were recruited; blood specimens were collected prior to cancer treatment. A performance evaluation study was designed utilizing reference set samples. Companies (n = 6) were selected to participate based on review of performance data and ability to utilize the blood collection tube. Companies received samples from cancer types their assay was designed to detect (“targeted”), plus additional “non-targeted” and control samples. Companies reported positive/negative calls, risk scores, and tissue-of-origin (TOO) predictions. Sensitivity was computed for early (I-II) and late (III-IV) stage cases, based on positive/negative calls (SEPN) and at fixed 98% specificity (SE98). Specificity and TOO accuracy were computed. Results Five hundred and forty nine cases (encompassing 13 cancer types) and 413 controls from the reference set were included in the study. Companies assessed samples from median 6 (range 5-9) targeted cancer types and median 8 (range: 7-11) overall cancer types. Median (range) specificity was 92.3% (76.5%-98.5%). Median (range) SEPN was 32% (25%-42%) for early stage and 73% (48%-89%) for late stage; while median (range) SE98 was 19% (8%-35%) for early stage and 66% (13%-79%) for late stage. Median sensitivity for non-targeted types was 40% (early stage) and 52% (late stage). Median (range) TOO accuracy (primary predicted site) was 75% (64%-78%). Conclusions Sensitivity and specificity varied widely across assays with early-stage sensitivity substantially lower than late-stage sensitivity. Clinical Trial Registration Number ClinicalTrials.gov identifier NCT05334069.
Delirium Detection Using Point-of-Care Single-Channel EEG: A Pilot Study
Heinze, Rebecca, Runkle, Tage L., Larson-Smith, Yvonne, Behnken, Emma , Shinozaki, Gen , Palmer, Allyson K.

Mayo Clinic

Innovation in Aging | January 3, 2026 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/geroni/igaf122.3744 Get It

Abstract Delirium is a common yet underdiagnosed medical emergency involving acute deficits in cognition and attention. It affects over 20% of hospitalized patients and up to 80% of ICU patients, with increased prevalence in older adults. Delirium is associated with increased mortality, prolonged hospitalization, long-term cognitive decline, and substantial healthcare costs. However, current screening tools are subjective and difficult to implement consistently. Traditional EEGs show diagnostic utility; however, they are costly and require specialized interpretation. We conducted a prospective pilot study evaluating a point-of-care, single-channel EEG device for delirium detection in hospitalized older adults. EEG spectra were utilized to calculate a ‘bispectral EEG’ (BSEEG) score reflecting the ratio of slow to fast brain waves. Twenty-two postoperative patients (mean age 75; 59.09% female) were assessed daily for up to seven days using both the BSEEG and the gold standard 3-Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM). ROC analysis was utilized to determine an optimal threshold BSEEG score to indicate delirium positivity. BSEEG scores were significantly higher in the 3D-CAM-positive group than in the 3D-CAM-negative group (1.60 and 1.45, respectively; p < 0.05). A BSEEG threshold of 1.5 demonstrated 77.78% sensitivity and 56.10% specificity for delirium. In contrast, route clinical screenings (Delirium Triage Screen and Brief CAM) showed 0.00% sensitivity and 96.30% specificity, and failed to detect all true delirium cases. Although further validation in larger cohorts is needed, these findings suggest that the point-of-care single-channel EEG is a promising, non-invasive screening tool for delirium screening, particularly in fast-paced clinical settings.
Drug‐resistant glutamic acid decarboxylase 65–associated epilepsy: Pre‐surgical evaluation and comparison to temporal lobe epilepsy of other etiology
Thomsen, Anna N., Dubey, Divyanshu, Britton, Jeffrey W. , Smith, Kelsey M., Dubey, Divyanshu , Smith, Kelsey M. , Ortiz-Guerrero, Gloria , Dubey, Divyanshu , Britton, Jeffrey W , Smith, Kelsey M , Ortiz‐Guerrero, Gloria

Mayo Clinic

Epilepsia | December 31, 2025 | Volume: 67 | Issue: 2 | Pages: No page available

10.1002/epi.70068 | PMID 41474363 Get It

Abstract High‐titer glutamic acid decarboxylase 65 (GAD65) antibodies (>20 nmol/L) are linked to chronic focal epilepsy, usually of temporal regional onset. Identification of these antibodies has treatment and prognostic implications. We compared patients with drug‐resistant epilepsy and high‐titer GAD65 antibodies to an age‐ and sex‐matched control group with drug‐resistant GAD65 antibody–negative temporal lobe epilepsy. From 1432 patients presented at a single‐center surgical epilepsy conference (2007–2024), we identified 15 patients (1% from surgical epilepsy conference: 13 female, 86.7%) with high‐titer serum GAD65 antibodies (median serum titer = 960 nmol/L; range 34–4678). The median age at epilepsy onset was 25 years (range 4–44). All had temporal regional‐onset epilepsy; 53% had bitemporal seizures. Three patients had limbic encephalitis, and three developed mesial temporal sclerosis. Those with GAD65 antibody–associated epilepsy were more likely to have depression and/or anxiety and less likely to undergo resection after evaluation than those in the control group. Although seizure types, electroencephalography (EEG), imaging, and autoimmune history were not statistically significantly different from the control group, we found that musicogenic seizures, limbic encephalitis, and type 1 diabetes occurred only in GAD65‐positive patients. These features, when present, may suggest an autoimmune etiology and warrant antibody testing. Identifying patients with GAD65 antibody–associated epilepsy is important due to its drug resistance, lower rate of satisfactory surgical outcomes, and potential responsiveness to immunotherapy. Further research is needed to define the optimal treatment and distinguish this subgroup from other causes of drug‐resistant epilepsy.
Bilateral Oophorectomy or Hysterectomy with Ovarian Conservation and Risk of Parkinson's Disease: A Systematic Review and Meta‐Analysis
Derhab, Mohamed , Ellabbad, Mohamed , Muhammad, Sara , Hamouda, Abdelrahman, Tawela, Ahmed, Okar, Lina , Savica, Rodolfo, Rocca, Walter A., Ellabbad, Mohamed , Hamouda, Abdelrahman M. , Smith, Carin Y. , Savica, Rodolfo , Rocca, Walter A.

Mayo Clinic

Movement Disorders Clinical Practice | December 31, 2025 | Volume: 13 | Issue: 6 | Pages: 1435-1445

10.1002/mdc3.70490 | PMID 41474091 Get It

Abstract Background The associations between bilateral oophorectomy or hysterectomy with ovarian conservation and the risk of Parkinson's disease (PD) remain inconclusive. Objectives To evaluate the evidence on these two associations. Methods We conducted a systematic search across Embase, PubMed, Scopus, MEDLINE, and Web of Science through May 15, 2024. Data were extracted independently by two reviewers, and random‐effects meta‐analyses were performed. Results Eight studies with a total of 242,275 women were included. For bilateral oophorectomy, the effect size (ES) was greater than 1.0 in 5 of 8 studies. The pooled analysis showed a significant association between premenopausal bilateral oophorectomy and an increased risk of PD in cohort studies (hazard ratio [HR] 1.32; 95% CI 1.12–1.56) but not in case–control studies or combining both cohort and case–control studies. There was a suggestive trend of increasing risk with younger age at bilateral oophorectomy. For hysterectomy with ovarian conservation, the ES was greater than 1.0 in all six studies. The pooled analysis showed a non‐significant association in cohort studies and in case–control studies; however, the association was significant when combining both cohort studies and case–control studies (ES 1.19; 95% CI 1.01–1.41). Conclusions Current studies provided low to moderate evidence for the associations between bilateral oophorectomy and hysterectomy with ovarian conservation and increased risk of PD. However, the evidence was only observational and there was important heterogeneity across the case–control studies. Future studies should focus on surgeries performed at younger ages and on the possible effects of estrogen replacement therapy.
Home Time Following Emergency Department Visits Among People With Dementia
Zepel, Lindsay , Smith, V. Kerry , Bellolio, Fernanda, Houtven, Courtney H. Van , Hastings, Susan N., Seidenfeld, Justine , Smith, Valerie A., Vashi, Anita A. , Hastings, S. Nicole

Mayo Clinic

JAMA Network Open | December 29, 2025 | Volume: 8 | Issue: 12 | Pages: e2549154

10.1001/jamanetworkopen.2025.49154 | PMID 41632170 Get It

Importance Emergency department (ED) visits for people with dementia often involve care (including the admission or discharge decision) with lasting effects on quality of life. Home time—a claims-based measure of days alive and outside of institutional care—provides a patient-centered way to assess downstream outcomes of ED care in this population. Objective To examine variations in home time following an ED visit by patient, facility, and visit characteristics among veterans with dementia. Design, Setting, and Participants This national retrospective cohort study used US Department of Veterans Affairs (VA) health care system data sources. Participants were veterans aged 65 to 110 years with dementia with an eligible Veterans Health Administration ED visit in fiscal years 2017 (October 1, 2016, through September 30, 2017) and/or 2018 (October 1, 2017, through September 30, 2018). Data were analyzed from May 1, 2024, to May 15, 2025. Exposures Patient, ED facility, and ED visit factors. Main Outcomes and Measures Home time, operationalized for modeling as days not at home in the 180 days after the index ED visit. Associations between patient, ED facility, and ED visit characteristics and home time were assessed using a negative binomial model. Results The study included 51 707 veterans with dementia (mean [SD] age, 79.9 [8.59] years; 97.6% male; 52.2% married). The mean (SD) number of days not at home within 180 days was 21.7 (34.5). Of the total cohort, 4.5% never returned home in the 180 days after their ED visit, while 18.2% had all subsequent days at home. ED admission (vs discharge) disposition was the factor associated with the largest increase in days not at home (rate ratio [RR], 3.18; 95% CI, 3.08-3.29). Patient factors associated with more days not at home included very high frailty (RR, 1.27; 95% CI, 1.21-1.33), unhoused status (RR, 1.50; 95% CI, 1.39-1.63), unmarried status (never married: RR, 1.24 [95% CI, 1.16-1.32]; divorced, separated, or widowed: RR, 1.24 [95% CI, 1.20-1.28]), and depression (RR, 1.13; 95% CI, 1.09-1.17). Conclusions and Relevance The findings of this cohort study suggest that home time offers a patient-centered measure of post-ED outcomes for individuals with dementia. Future work should refine its application, particularly regarding the ED disposition decision, to better evaluate the long-term impact of ED care decisions.
Home Time After an Emergency Department Visit by People Living with Dementia
Zepel, Lindsay , Smith, V. Kerry , Bellolio, Fernanda, Houtven, Courtney H. Van , Hastings, S. Nicole, Seidenfeld, Justine , Smith, Valerie, Vashi, Anita A. , Hastings, Susan N.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S4 | Pages: No page available

10.1002/alz70858_099407 Get It

Abstract Background People living with dementia (PLWD) face short‐term risks following emergency department (ED) visits. However, the long‐term impacts of ED visits on PLWD quality of life are not well characterized. Home time‐ days alive and outside hospitals or other care settings‐ is an emerging measure that can reflect longer‐term outcomes. We aimed to identify patient and ED visit characteristics associated with variation in home time after an ED visit. Method Retrospective observational study of Veteran PLWD with ≥1 VA ED visit between 10/01/2016 and 09/30/2018. We used VA and CMS data sources to define veteran characteristics and outcomes. Primary outcome was home time in the 180 days after an ED visit, defined as days alive and not in an ED, inpatient, post‐acute, or a nursing home setting. We used a negative binomial model to evaluate the associations between covariates and home time with VAMC‐level random effects to account for correlation among patients at the same VAMC. Result Our final cohort comprised 51,707 Veteran PLWD, predominantly male (97.6%) and white (73.0%), with mean age 79.9 (SD 8.59). Most lived in urban areas (74.4%), and 52.2% were married. Characteristics associated with reduced home time included older age (RR 1.06, 95% CI 1.05‐1.07), never married (RR 1.24; 1.16‐1.32) or divorced/widowed (RR 1.24; 1.20, 1.28), depression (RR 1.13; 1.09, 1.17), and ED visits for chronic conditions (RR 1.13; 1.08, 1.18). Female sex (RR 0.88; 0.79‐0.97) and lower clinical frailty (RR 0.79; 0.75, 0.83) were associated with more home time. Conclusion Patient and ED visit characteristics impact home time up to 180 days after an ED visit. Older, frailer, unmarried, male patients and those presenting with chronic conditions experienced reduced home time, suggesting directions for targeted interventions. Efforts such as enhanced discharge planning and addressing psychosocial factors (e.g., depression) could improve quality of life.
Association of Plasma Biomarkers of Alzheimer's Disease with Incident Tau PET Positivity
Graff‐Radford, Jonathan, Syrjanen, Jeremy A. , Vemuri, Prashanthi, Lowe, Val J. , Wiste, Heather J. , Schwarz, Christopher G, Therneau, Terry M. , Binette, Alexa Pichet, Smith, Ruben, Mattsson‐Carlgren, Niklas, Palmqvist, Sebastian, Knopman, D., Cogswell, Petrice M, Petersen, Ronald, Hansson, Oskar H., Jack, Clifford R., Graff‐Radford, Jonathan , Vemuri, Prashanthi , Schwarz, Christopher G. , Algeciras‐Schimnich, Alicia , Binette, Alexa Pichet , Smith, Ruben , Mattsson, Niklas , Palmqvist, Sebastian , Stomrud, Erik , Cogswell, Petrice M. , Petersen, Ronald, Hansson, Oskar , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_098904 Get It

Abstract Background The objective of this study was to determine the predictive value of amyloid‐PET versus plasma %p‐tau217 (defined as the ratio of phosphorylated to non‐phosphorylated Tau217 × 100), Aβ42/40, and the amyloid probability score (APS2; which combines of Aβ42/40 and %p‐tau217) in tau‐PET transitions (T‐ to T+). Method Participants included were from the Mayo Clinic Study of Aging (MCSA) and had plasma markers measured by mass spectrometry (IP‐MS; C2N), had an amyloid‐PET scan, and had a tau‐PET negative scan (SUVR<1.29, temporal meta‐ROI) at the baseline, along with one or more follow‐up tau‐PET scans. Cox proportional hazard models were used to evaluate the relationship between C2N plasma %P‐Tau217 and APS2 and incident tau‐PET positivity (SUVR>=1.29) adjusting for age, sex, and APOE ε4. An analysis was also performed using amyloid‐PET centiloid as the predictor. Both the plasma markers and amyloid‐PET centiloid were scaled so that a one‐unit change corresponds to the respective interquartile range (IQR) for comparability of hazard ratios (HR). The analyses were repeated in the BioFINDER‐2 cohort for validation. Result 255 MCSA participants (122 female [47.8%] were included with a median age of 71.9 (IQR: 65.8, 78.8) years old, of which 37 progressed to tau‐PET positivity. At baseline, 238 (93.7%) were cognitively unimpaired. Higher baseline %p‐tau217 (HR: 1.52 [95% CI: 1.28, 1.8]), amyloid‐PET centiloid (HR: 1.47 [95% CI: 1.20, 1.79]), and APS2 (HR: 1.62 [95% CI: 1.22, 2.16]) were associated with an increased risk of progressing to tau‐PET positive (Figure 1). Aβ42/40 (HR: 1.06 [95% 0.604–1.867] was not associated with incident tau positivity Among 605 participants who were tau negative at index date in BioFINDER‐2 (316 (52.2%) cognitively unimpaired), with a median age of 70.2 (IQR: 60.5‐76.4), 33 progressed to tau positivity with higher %p‐tau217 (HR: 1.8 [95% CI: 1.5, 2.17]), amyloid‐PET centiloid (HR: 2.3 [95% CI: 1.77, 2.97]), and lower Aβ 42/40 (HR: 0.42 [95% CI: 0.21, 0.85]) at index date all associated with an increased risk of progressing to tau‐PET positive. Conclusion In two independent cohorts , %p‐tau217 provides predictive information about those who will convert from tau negative to tau positive on PET scan with the associations being similar to amyloid‐PET.